“It gives the tick on all four, it does look promising and it should launch,” Gail Bekker said. “We wanted to see a particular immune picture that would suggest that a big efficacy trial would be likely to yield results,” she said.
“[This] was like the gatekeeper of will we or will we not go ahead,” Fauci said, “and the answer is ‘yes’.
A larger-scale trial of the vaccine will now begin in 5,400 people across four sites in South Africa in November 2016 and run for three years. A fifth dose of the vaccine will also be given in hope of longer-lasting protection.
The Thai study showed 60% protection against HIV after one year, but this fell to 31% by the end of the trial. The team hopes the new regimen will bring protection levels back up.
“We want to get it up to 60% and keep it there,” Fauci said. “That’s the reason for the boost and the reason for the adjuvant,” he said.
Experts have long been awaiting a vaccine showing enough efficacy to dent the numbers of people newly infected with HIV each year, which fell by 0.7% between 2005 and 2015, according to a study published Tuesday and presented at the conference.
CONTINUE READING ON PAGE 4 FOR MORE